Molecular characterization of atherosclerosis in HIV positive persons

Adam Cornwell1, Rohith Palli2,3, Meera V. Singh4, Lauren Benoodt3, Alicia Tyrell5,6, Jun-ichi Abe7,8, Giovanni Schifitto5,6, Sanjay B. Maggirwar9 & Juilee Thakar1,4,10,*

People living with HIV are at higher risk of atherosclerosis (AS). The pathogenesis of this risk is not fully understood. To assess the regulatory networks involved in AS we sequenced mRNA of the peripheral blood mononuclear cells (PBMCs) and measured cytokine and chemokine levels in the plasma of 13 persons living with HIV and 12 matched HIV-negative persons with and without AS. microRNAs (miRNAs) are known to play a role in HIV infection and may modulate gene regulation to drive AS. Hence, we further assessed miRNA expression in PBMCs of a subset of 12 HIV+ people with and without atherosclerosis. We identified 12 miRNAs differentially expressed between HIV+ AS+ and HIV+, and validated 5 of those by RT-qPCR. While a few of these miRNAs have been implicated in HIV and atherosclerosis, others are novel. Integrating miRNA measurements with mRNA, we identified 27 target genes including SLC4A7, a critical sodium and bicarbonate transporter, that are potentially dysregulated during atherosclerosis. Additionally, we uncovered that levels of plasma cytokines were associated with transcription factor activity and miRNA expression in PBMCs. For example, BACH2 activity was associated with IL-1β, IL-15, and MIP-1α. IP10 and TNFα levels were associated with miR-124-3p. Finally, integration of all data types into a single network revealed increased importance of miRNAs in network regulation of the HIV+ group in contrast with increased importance of cytokines in the HIV+ AS+ group.

Studies of human immunology highlighting variability across individuals have revealed that variation in functional responses is largely determined by non-heritable factors, most likely by environmental exposures2–3. Viral infections such as human immunodeficiency virus type-1 (HIV) interfere with cellular targets and cause derangement of the immune response. Combination anti-retroviral therapy (cART) has rendered HIV infection as a chronic manageable disease. However, persons living with HIV remain at increased risk of co-morbidities despite cART; the most frequent of these is cardiovascular disease (CVD) driven by atherosclerosis (AS)4–6. It is likely that cART and HIV itself play a role in AS7. This observation was also reported in a study that assessed carotid artery thickening, a marker of AS, which was up to 24% higher in persons living with HIV compared with uninfected sex- and age-matched persons, and was comparable in cART-naïve persons and with virologic suppression on cART8. Moreover, a large retrospective analysis indicates that HIV infection status independently confers an odds ratio for acute myocardial infarction of ~ 1.93 (95% CI, 1.21–2.93) after adjusting for traditional risk factors such as age and hypertension9. Other more recent studies also support this observation9–11. Thus, persons living with HIV are at higher risk of AS even with ongoing cART therapy8,12,13. Moreover, elevated AS prevalence in HIV-1 elite controllers indicates that inflammation can be induced by the presence of HIV infection14.

AS is triggered by a pro-thrombotic inflammatory environment that attracts platelets and monocytes to injured endothelial cells. As monocytes migrate into the vessel wall, they differentiate into macrophages.

1Department of Biomedical Genetics, University of Rochester, Rochester, NY, USA. 2Medical Scientist Training Program, University of Rochester, Rochester, NY, USA. 3Biophysics, Structural, and Computational Biology PhD Program, University of Rochester, Rochester, NY, USA. 4Department of Microbiology and Immunology, University of Rochester, Rochester, NY, USA. 5Department of Neurology, General Neurology, University of Rochester, Rochester, NY, USA. 6Department of Imaging Sciences, University of Rochester, Rochester, NY, USA. 7Department of Cardiology-Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 8Texas A&M Health Science Center Institute of Biosciences and Technology, Houston, TX, USA. 9Department of Microbiology, Immunology, and Tropical Medicine, George Washington University, Washington, DC, USA. 10Department of Biostatistics and Computational Biology, University of Rochester, 601 Elmwood Avenue, Box 672, Rochester, NY 14642, USA. *email: juilee_thakar@urmc.rochester.edu
Macrophages exert their phagocytic activity, engulfing lipids, and forming the characteristic foam cells. These cells release further chemoattractant molecules, maintaining a process that leads to plaque formation. Several molecular mechanisms induced by HIV infection and cART therapy lead to persistent inflammation and contribute to development of AS. Treatment with cART is associated with increased cholesterol levels, a risk factor for AS. HIV infection itself leads to higher levels of oxidized low density lipoprotein (LDL), which increases endothelial expression of monocyte and T cell adhesion markers. Oxidized LDL, cholesterol crystals, and HIV infection itself activate the macrophage/microvascular inflammation, which drives inflammation through activation of cytokines such as IL-18 and IL-1β.

Cytokines and other soluble secreted signaling molecules, such as chemokines, regulate inter- and intracellular signaling, thus driving pathogenesis of HIV or AS. A handful of such interactions are known: for example, IL-21 promotes STAT3-mediated expression of miR-29 which in turn inhibits antiviral gene expression and resistance to HIV infection in CD4+ T cells. Stimulation of macrophages with a combination of IFN-γ and mildly-oxidized LDL induces miR-155 expression and results in higher levels of the MCP-1/CCR2 chemokine and further promotes inflammation through inhibition of the transcription factor BCL6. However, cytokine-miRNA-mRNA networks in persons with HIV who also have atherosclerosis have yet to be fully characterized. Thus, further study of cytokines together with miRNA is warranted to understand the interaction between HIV and atherosclerosis.

Micro-RNAs (miRNAs or miRs) may be a major factor in the complex pathophysiology of AS. miRNAs are short non-coding ribonucleotide molecules, typically 22 nt, that serve as critical regulators of gene expression across nearly all life stages and tissues. miRNA dysregulation has been linked to AS through effects on cholesterol metabolism, lipid uptake by macrophages, inflammation, and angiogenesis. A number of miRNAs have been suggested as potential therapeutic targets and biomarkers for AS, as well as other diseases and environmental exposures. miRNAs include miR-126-5p which has been implicated in angiogenesis to lipopolysaccharide stimulation when levels are altered in persons with HIV infection, and miR-132 which is associated with CD4+ T-cell activation and increased HIV replication, and let-7c, miR-34a, and miR-124a which modulate innate immune activity, among others. Of the miRNAs with altered expression in HIV infection, some have been studied as putative biomarkers of AS in HIV infection or have been previously associated with AS, including miR-210, miR-7, and miR-331, miR-155 and miR-223, miR-125a-5p and miR-139-5p, miR-132, and miR-126, miR-145, and let-7c. How miRNAs are dysregulated in AS and chronic HIV infection, and the targets they modulate to act as effectors of inflammation in those contexts remains unclear.

Given the complex roles of miRNAs, cytokines, and signaling events, here we aim to use systems-level approaches to investigate dysregulated networks involved in development of AS in people living with HIV. Though atherosclerosis itself is a tissue-specific pathogenesis, chronic, systemic inflammation (which is a hallmark of HIV infection) is one of the major drivers of AS progression. In that regard, PBMCs provide insights into systems-level changes and are frequently used as a proxy to investigate tissue- and organ-specific modulations. Specific to HIV infection, various components of anti-retroviral therapy and viral proteins exert inflammatory/activatory effects on monocytes/macrophages as shown by our group and others. Of the miRNAs with altered expression in HIV infection, some have been studied as putative biomarkers of AS in HIV infection or have been previously associated with AS, including miR-210, miR-7, and miR-331, miR-155 and miR-223, miR-125a-5p and miR-139-5p, miR-132, and miR-126, miR-145, and let-7c. How miRNAs are dysregulated in AS and chronic HIV infection, and the targets they modulate to act as effectors of inflammation in those contexts remains unclear.

Levels of pro- and anti-inflammatory mediators in peripheral blood plasma. A 29-Plex Milliplex Human Cytokine/Chemokine panel kit (Millipore Cat# HCYTMAG-60K-PX29) was used to quantitate the cytokine and chemokine levels using Lumineex magnetic microbead array technology. The assay was performed according to the manufacturer’s instructions. In brief, plasma specimens were thawed on ice and micro-centrifuged for 5 min at 15,000 RCF at 4 °C to remove any particulate matter. 25 μLs of reference standard dilutions, control, and test specimens were incubated overnight at 4 °C with shaking at 800 RPM in duplicate wells on a 96 well plate with 25 μLs of either assay buffer for specimens or plasma matrix for standards and controls and 25 μLs of microbead solution. Wells were washed 3 times with wash buffer on an automated magnetic plate washer (Bio-Rad Bio-Plex ProII) and 25 μLs of biotinylated detection antibodies were added for 1 h at room tempera-
Peripheral blood mononuclear cell isolation and RNA-sequencing. mRNA and micro-RNA were isolated and sequenced from PBMCs at the UR Genomics Research Center using their standard protocols. mRNA libraries were prepared with the Illumina TrueSeq Kit v2, using oligo-dT beads for poly-A selection. mRNA was sequenced as single-ended 100 bp reads, yielding an average of 26.7 million reads per sample, for a total of 25 samples, representing four sample groups (normal control, n = 6; AS+, n = 6; HIV+, n = 6; HIV+ AS+, n = 7). Reads were trimmed with Trimmomatic to remove low-quality read tails or entire reads if the remaining post-trim read length was too short. Genome mapping was performed with STAR 2.5.2b to Human genome GRCh38.p7 with annotation from Gencode Genes version 25. Read counting was performed with the feature-COUNTs from Subread. Count data is available in Supplemental Table 3. Small RNA was size-selected from total RNA and libraries were prepared with the Illumina TrueSeq Small RNA kit. Small RNA was sequenced as single-ended 50 bp reads, with an average of 17 million reads per sample, for a total of 12 samples representing two sample groups (n = 6 each for HIV+ and HIV+ AS+). Reads were trimmed, mapped, annotated, and counted with the mirGe pipeline65. Count data is available in Supplemental Table 4. miRNA were mapped to cell types using an available catalogue of miR expression in blood cell types59.

RNA-sequencing analysis. Small RNA-seq and mRNA-seq datasets were read into R (version 3.5.1)37, and filtered to remove sequences with low expression based on raw counts. For mRNA, any gene with fewer than 10 reads in all samples was excluded, leaving 19,861 genes for annotated gene types which may be polyadenylated (protein coding, lincRNA, and processed pseudogenes). For miRNA, any miRNA with fewer than 10 reads in all samples was excluded, yielding a set of 778 miRNAs used for downstream analyses. Exploratory analysis of each dataset (e.g. clustering, expression heatmaps, PCA) was performed on variance-stabilized transformed (VST) counts, as computed by the DESeq2 package (version 1.22.2)58. Differential expression analysis was performed with DESeq258 for both mRNA and miRNA (independently). The results of differential gene expression analysis for miRNA in all genes in the dataset are available in Supplemental Table 5, and differentially expressed miRNAs are available in Supplemental Table 6. For mRNA, groupwise comparisons were performed a corrected (FDR) p-value and fold-change cutoffs are noted in the results. Predicted miRNA target genes were found for differentially expressed miRNAs with the miRAtap package (version 1.16.0)60 which incorporates predictions from five algorithms: DIANA, Miranda, Targetscan, PicTar, and miRDB. A given miR-target relationship was recorded if it was supported by at least two of the five prediction algorithms. The predicted targets of differentially expressed miRNAs are available in Supplemental Table 7, while functional enrichment analysis on these targets is available in Supplemental Table 8.

miRNA expression across normal human blood cells. Publicly available miRNA expression data across normal human blood cells were downloaded from GEO (GSE100467)36, and read into R with the BioConductor package IsoMirs (version 1.10.1)46 to obtain read counts for each of the 450 samples, representing ten cell populations from 162 unique donors. A matrix of raw counts was assembled by joining the individual sample results with dplyr, and miRNAs with very low counts (< 3) across all samples were excluded, leaving 1062 unique miRNAs with expression in at least one sample. Variance-stabilized (VST) and library-normalized counts were obtained with DESeq2. To obtain a summary of expression of each miRNA for each cell type, miRNA abundances were discretized in 5 levels, with higher-value bins representing higher expression. The number of bins was determined by ceiling (\(\sqrt{\text{max}(n)}\)), where n is the number of samples for each cell type. Relative levels of miRNA expression in each cell-type was given by the median of the discretized values.

Data integration analysis. Three types of data integration were performed: (1) miRNA and mRNA (2) cytokine and mRNA and (3) cytokine, mRNA and miRNA datasets were combined. Predicted miRNA targets were further filtered based on their significant negative correlation with miRNA (p < 0.05, r ≤ −0.5). Linear discriminant analysis (LDA) was performed on predicted miRNA target genes to identify genes that distinguish between HIV+ AS− and HIV+ AS+ samples. To identify transcriptional changes associated with cytokine levels, a single person transcription factor score (spTFscore) was calculated. Particularly, transcription factor (TF) target gene expression in each person. Pearson correlation was measured between all plasma cytokines and spTFscore. TF target gene weights were calculated as contributions to spTFscore by \(\frac{\sum_{i=1}^{m} w_i^2 v_i}{\sum_{i=1}^{m} v_i^2}\), where \(w_i\) is the loading of the gene in that
with inflammation. Comparison between the HIV+ AS+ and control groups revealed five genes higher in one common genes among the two contrasts, integrin alpha D (ITGAD/CD11d), which is strongly associated with BACH2. It is known that Bach2–Batf interactions are required to prevent an excessive Th2 response.

The correlation between cytokine levels and the spTFscore revealed regulation by different arms of the immune system. Specifically, Th1, Th17 signature cytokines along with TNFα, MIP-1α and GCSF were associated with BACH2. It is known that Bach2–Batf interactions are required to prevent an excessive Th2 response. IP-10 was associated with several transcription factors such as IRF1 and CEBPα. Further analysis indicated that predicted targets of these transcription factors have little overlap, suggesting diverse transcriptional programs potentially associated with IP-10.

To investigate transcriptional changes in this highly variable data, we developed a single person transcription factor score (spTFscore) that could be compared with cytokine levels to identify transcription factors regulated by cytokines. The correlations between cytokine levels and the spTFscore revealed regulation by different arms of the immune system. Specifically, Th1, Th17 signature cytokines along with TNFα, MIP-1α and GCSF were associated with BACH2. It is known that Bach2–Batf interactions are required to prevent an excessive Th2 response.

Many target genes of TFs significantly associated with the cytokines were differentially expressed (p-adj < 0.1 and LFC > 1.0) between HIV+ vs HIV+ AS+ group and HIV+ vs healthy (Fig. 2). The genes differentially expressed between HIV+ vs healthy and targets of TFs associated with IP10 include genes implicated in HIV infection e.g. CCR4, CCR6 and KIF19. CCR4+ and CCR6+ CD4+ T cells are highly permissive to HIV replication. Interestingly, IP-10 enhances the recruitment of HIV-target cells and is a biomarker of early disease onset.

We also evaluated additional genes different at p-adj < 0.1 and LFC > 1.0 and associated with either HIV infection or AS (Supplementary Table 5). ATP1A2 is an Na+/K+ pump component involved in smooth muscle contraction, and it is differentially expressed in vasculature between myocardial infarction (MI) and stable angina, and is also differentially expressed in our data between HIV+ and HIV+ AS+. SLIT2 is a known inhibitor of HIV transmission that was significantly elevated in HIV+ vs control. GPR15 is a co-receptor for HIV and a possible biomarker for smoking status. It had increased expression in HIV+ AS+ than HIV+ group. In this context, it may be a marker for the deleterious interaction between HIV and smoking status, which leads to atherosclerosis.

In conclusion, transcriptional changes and their relation with cytokine levels reveals several dysregulated interactions contributing to AS in the context of HIV and suggests further risk in HIV+ persons.

Characterization of micro-RNAs in HIV+ persons with carotid plaques. We performed genome-wide miRNA sequencing in HIV+ persons with (n = 6) and without (n = 6) carotid plaques. All 12 participants were males of ≥50 age to minimize the inter-person variation and maximize the differences across disease/infection groups in this small study. Moreover, in this focused group confounding variables were balanced, increasing the statistical power. Sequencing yielded at least 15 million short reads per sample, and most reads
were ~ 22 nt after trimming, the typical length of miRNAs, indicating successful size selection and good read quality. Less than 10% of reads remained unmapped in all cases. miRNAs were identified and quantified from sequencing data with the miRge pipeline. 778 miRNAs were considered after filtering out miRNAs that did not have at least 10 reads in all samples. Differential expression analysis identified 12 microRNAs with significant expression changes, out of which 3 were higher in HIV+ subjects with AS and 9 were higher in HIV+ subjects without AS (Fig. 3A).

A subset of these differently expressed miRNAs that have been previously implicated in cardiovascular disease are discussed below. High miR-124-3p indicated susceptibility to atherosclerosis in a population of smokers. In our dataset, miR-124-3p had no or very low expression in HIV+ AS− samples, but was found in 5 of 6 HIV+ AS+ samples (only two of which were identified as current smokers) indicating that the elevated level of miR-124-3p may be indicative of AS risk outside of the context of smoking. Another miRNA, miR-182-5p is found to be upregulated about two times in myocardial infarction vs controls in whole blood samples, however this miRNA was downregulated in HIV+ persons with AS compared to without. miR-34a-5p is expressed in T-cells (CD3+ and CD4+), and is negatively correlated with T-cell counts after HIV infection, possibly due to lysis of T-cells. miR-34a-5p has also been shown to be increased in heart failure and decreased in peripheral arterial disease, in addition to being upregulated in endothelial progenitor cells from coronary artery disease patients. In ApoE-deficient mice fed a “western-style” diet for 16 weeks, the mice developed severe atherosclerotic lesions and exhibited progressive upregulation of miR-34a-5p. In accordance with these observations linking higher levels of miR-34a-5p to AS, we find this miRNA to be elevated in most of our HIV+ AS+ samples compared to HIV+ alone.

Figure 1. Association of activity of transcription factors (TFs) with cytokine and chemokine levels in plasma. Activity of the TFs was measured by single person transcription factor (spTF) scores. spTF was calculated as described in the methods. Briefly, TF targets as described in were used to perform PCA and subject specific PC scores were used to calculate Pearson correlation (ranging from low to high depicted by white to red color bar) with cytokine levels. The significant correlations (p < 0.05) are indicated with stars. Analysis and graphical output done using R (ver 3.5.1)
**Figure 2.** Gene targets of transcription factors correlated with cytokine and chemokine levels in plasma. Expression of the differentially expressed targets (p-adj < 0.1, LFC > 1.0 in any comparison) of transcription factors from Fig. 1. Expression shown as z-scores across all four groups (indicated by top bar). The weight of each gene in determining spTF score is shown on left (white to red color bar) as the percentage of the variance accounted by the gene. Analysis and graphical output done in R (ver 3.5.1).
To validate the miRNAs identified by RNA-seq we performed RT-qPCR on 5 miRNAs in ten participants (Fig. 3C). The miRNAs miR-144-3p, miR-144-5p, miR-183-5p, miR-451a and miR-4732-3p were chosen based on the largest fold change between HIV+ AS+ vs HIV+ AS−. The samples were run in pairs as shown in Fig. 3C. All of the 5 miRNAs were lower in HIV+ AS+ compared to HIV+ AS− in RNA-seq experiments. RT-qPCR validated this observation when a subset of the same samples from RNA-seq were used. Among the new independent samples one pair showed an opposite direction, whereas all other samples validated the observations from RNA-seq. The five validated miRNAs are novel and very little is known with respect to their role in HIV infection and atherosclerosis. miR-144-3p 92,93 and miR-183-5p94 have been linked atherosclerosis, cholesterol metabolism, and HIV infection in different organisms and model systems. In consensus with our observations miR-451a has been found to be reduced in circulation of subjects with coronary heart disease95.

To investigate which specific cell-types are known to express the differentially expressed miRNAs from our study, we used a public compendium of miRNA expression across human blood cell types56. Specifically, expression of differentially expressed miRNAs was investigated in the public compendium to determine the cell types that normally express the differentially expressed miRNAs (Supplemental Fig. 1). This analysis revealed that only miR-486-5p was ubiquitously expressed, and that the other DE miRNA may exhibit low or no expression in normal CD8+ or CD4+ T cells and CD14+ monocytes (Supplemental Fig. 1). To further characterize the effect of these miRNAs, we performed pathway analysis of their predicted targets (Fig. 3B). Importantly, similar to previous findings, miR-124-3p was enriched in ‘Signaling to ERKs’ and ‘Activation of AMPA Receptors’. miR-183-5p was associated with a number of pathways including the ‘Twik related potassium channel (TREK)’, ‘Signaling by WNT’ and ‘Neuronal System’. The analysis for (A,B) done in R (version 3.5.1).

Figure 3. Dysregulation of miRNAs during atherosclerosis in HIV positive persons: (A) Differentially expressed miRNA counts. HIV+ samples shown on left (pink bar on the top) and HIV+ AS+ on right (orange bar on the top). miRNAs are clustered hierarchically with directionality shown by a left red (high in HIV+ group)/blue (high in HIV+ AS+ group) color bar66. (B) Pathway analysis of predicted target genes of DE miRNA. Dots represent significantly enriched pathways with color representing p-value and size of dot representing proportion of target genes in the pathway. (C) Fold-ratio of selected miRNAs in HIV+ AS− (Plq−) and HIV+ AS+ (Plq+) samples, as measured by RT-qPCR. Samples included a subset of those previously profiled by miRNA-Seq (orange triangles), as well as new samples (green circles). Graphical output for (A–C) and analysis for (A,B) done in R (version 3.5.1).
Role of miRNAs in regulatory networks. miRNAs are important regulators of mRNA turnover and are thought to regulate 10–30% of mRNAs96–100. miRNAs function post-transcriptionally via the RNA-induced silencing complex (RISC) to inhibit mRNA. Hence, we found predicted targets of differentially expressed miRNAs that also had significant negative correlation with mRNA expression in our data. A set of 27 of these genes with highest loadings from Linear Discriminant Analysis (LDA) was sufficient to differentiate the HIV+ AS+ and HIV+ AS− groups (Fig. 4A). This list included genes such as SPRED1 which is involved in IL-15 and FGFR1 signaling, GRK6 which is involved in the myometrial relaxation and contraction pathway and calcium regulation in cardiac cells, and RAN which is involved in the export of viral ribonucleoprotein. Also in this set of 27 genes is SLC4A7, a critical sodium and bicarbonate transporter involved in generation of Nitric Oxide (NO) signaling and blood pressure regulation; NO signaling has been linked to AS risk101. Importantly, 15/27 of these genes are upregulated in HIV+ AS+ vs HIV but downregulated in AS vs healthy control with no correlation between the two changes, indicating that these genes describe an HIV-specific atherosclerosis state (Fig. 4B).

miRNAs can be transcriptionally regulated by cytokine signaling102 while cytokine production103 and signal transduction can be influenced by miRNAs104,105. Hence, we asked which cytokines are significantly associated with DE miRNAs. IL-8 was positively associated with most of the miRNAs but negatively associated with miR-124-3p (Fig. 4C). miR-124-3p, which regulates ERK signaling and activation of AMPA receptors, was also negatively associated with MIP-1α but positively associated with TNFα and IP10 (also known as CXCL10). IP10 is induced during antiviral response and was higher in HIV+ and HIV+ AS+ groups (not statistically significant, p = 0.08). Numerious studies have reported abnormally high plasma IP-10 levels in the context of HIV infection, and IP10 is considered an important pro-inflammatory factor in the HIV disease process106. IP-10 and TNFα are both associated with miR-124-3p (Fig. 4C) and are highly expressed in HIV+ AS+ group. As discussed before, we found IP10 to be associated with diverse transcriptional programs activating several genes implicated in HIV infection. The role of miR-124-3p in this regulation needs to be further investigated. IL8 has interactions with miRNA in a number of diseases and conditions107. Other miRNAs have been found to de-repress expression of IL6 and IL8 in a cell-based model of sepsis108. These results suggest novel regulatory relationships between miRNAs and IL-8; however, IL-8 levels were not different in HIV+ persons with and without AS. IL-8 expression (at both the gene and plasma levels) has been reported to be significantly elevated in HIV-infected children that were not yet receiving ART therapy, and decreased after therapy began109. Several additional associations were found between miRNAs and cytokines (Fig. 4C). Thus, this work suggests a role for pro-inflammatory cytokines in regulating miRNAs which can in turn regulate gene programs.

Integrated network of cytokines, miRNA and mRNA. Finally, having established several links between cytokines, miRNAs, and mRNAs in a pairwise manner, we set out to investigate such interactions systematically. Hence, we constructed a network, incorporating all three data types—mRNA, miRNA, and cytokine profiles, for HIV+ and HIV+ AS+ groups. The network includes 175 genes, 23 cytokines and 10 miRNAs (Fig. 5, Supplementary Table 1). Differential network analysis using eigenvector centrality identify nodes with higher importance with AS in the context of HIV.

Higher centrality of cytokines and chemokines compared to the genes was expected because a small number of cytokines measured were connected to many miRNAs and genes. Three cytokines, IL1β, IL15, and MIF1α, which were also associated with BACH2 were more central in HIV+ AS+ than HIV suggesting their role in regulating mRNA and miRNA expression in persons living with HIV and atherosclerosis. IL13, IL5, TNFβ, and IL1-RA associated with ZBTB7C, were more central in HIV than HIV+ AS+ groups, along with hsa-miR-144-5p, hsa-miR-451a, and hsa-miR-182-5p. hsa-miR-451, one of the miRNA independently validated in this study, has been shown in rats to target the IL6 receptor in arterial smooth muscle cells110, and IL-6 knockdown in mice induced release of cytokines including IL6, TNF, CCL5/RANTES, and CCL3/MIP1α111. This is corroborated by increased centrality of these downstream cytokines in the HIV+ AS group. hsa-miR-182-5p, on the other hand, is a pro-atherosclerotic AKT1-inhibitor implicated in acute coronary disease (atherosclerosis of the heart)112 via endothelial cell dysfunction. Positive association between pro-AS miRNAs and anti-inflammatory/anti-AS cytokines such as IL5113 might suggest a compensatory response that delays AS. Thus, our network analysis identifies two critical atherosclerosis-related miRNAs— hsa-miR-182-5p which affects endothelial cells, and hsa-miR-144-5p (also validated by RT-qPCR) which affects macrophages, known to be elevated in high viral titer HIV infection.

Conclusion

Taken together, this study revealed novel miRNAs differentially expressed in AS+/− people living with HIV, and identified many interesting interactions of miRNAs with cytokines. Centrality measures indicate that miRNAs display importance in regulating molecular networks in people living with HIV, whereas cytokines play a greater role in people living with HIV and AS. Though mRNA measurements were highly variable even with very strict subject selection criteria, novel computational approaches such as single person transcription factor score, and leveraging public domain datasets, provided insights about regulatory factors. Nevertheless, several findings in
Figure 4. Interaction of miRNA expressed in PBMCs with mRNA expression in PBMCs and cytokines and chemokines levels in plasma: (A) miRNA target genes were identified using miRNAtap package and were further filtered to keep only genes whose expression was negatively correlated with the expression of their regulator miRNA. The filtered genes were analyzed by Linear Discriminant Analysis (LDA) and 27 target genes were selected based on separation between AS+ (yellow)/− (purple) groups. PCA with 27 genes are shown (s). (B) Log2 fold change of HIV+ AS+ vs HIV+ and AS+ vs healthy control for 27 target genes. (C) Association of miRNA with cytokine and chemokines using the data from HIV+ AS+ and HIV+ AS− groups. Spearman correlation; significant associations are indicated with stars (*p-value < 0.05, **p-value < 0.005, ***p-value < 0.001). Analysis and graphical output done in R (ver 3.5.1).
Figure 5. Regulation of AS associated signaling in the context of HIV. The network of association between miRNA, mRNA and cytokines in HIV+ people with and without AS. Squares represent miRNA, circles represent mRNA and diamonds represent cytokines and chemokines. Coloring of nodes indicates centrality score for HIV+ AS+ group (top) or HIV group (bottom). Coloring of edges represents sign of correlation between nodes in HIV+ or HIV+ AS+ groups as shown in the edge color key. Analysis performed in R (ver 3.5.1)\textsuperscript{57}, with graphical output from Cytoscape (version 3.7.0)\textsuperscript{67}.
this study require future validation in larger cohorts with more demographic variables and further expansion of the experimental groups.

Received: 19 February 2020; Accepted: 30 December 2020
Published online: 05 February 2021

References
1. Brodin, P. et al. Variation in the human immune system is largely driven by non-heritable influences. Cell 160, 37–47 (2015).
2. Brodin, P. & Davis, M. M. Human immune system variation. Nat. Publ. Gr. https://doi.org/10.1038/nri.2016.125 (2016).
3. Liston, A., Carr, E. J. & Linterman, M. A. Shaping variation in the human immune system. Trends Immunol. 37, 637–646 (2016).
4. Currier, J. S. et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 118, e29-35 (2008).
5. Triant, V. A., Lee, H., Hadigan, C. & Grinspoon, S. K. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J. Clin. Endocrinol. Metab. 92, 2506–2512 (2007).
6. Triant, V. S. et al. Coronary heart disease in HIV-infected individuals. J. Acquir. Immune Defic. Syndr. 33, 506–512 (2003).
7. Singh, M. V. et al. Senescent phenotype induced by p90RSK-NRF2 signaling sensitizes monocytes and macrophages to oxidative stress in HIV-positive individuals: Implications for atherogenesis. Circulation 139, 1199–1216 (2019).
8. Lorenz, M. W. et al. Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis 196, 720–726 (2008).
9. Freiberg, M. S. et al. MicroRNA-126, -145, and -155: a therapeutic triad in atherosclerosis. Cell 164, 37–47 (2015).
10. Corti, R., Hutter, R., Badimon, J. J. & Fuster, V. Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis. J. Thromb. Thrombolysis 17, 35–44 (2004).
11. Currier, J. S. et al. HIV infection and the risk of acute myocardial infarction. J. Acquir. Immune Defic. Syndr. 51, 268–273 (2009).
12. Mary-krause, M., Cotte, L., Simon, A. & Partisani, M. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men Dominique Costagliola, a, and the Clinical Epidemiology Group from the French Hospital Database. AIDS https://doi.org/10.1097/01.aids.0000968557.36052.23 (2003).
13. Roque, V. L. et al. Heart disease and stroke statistics—2012 update. Circulation 125, 2–220 (2012).
14. Deeks, S. G. HIV infection, inflammation, immunosenescence, and aging. Annu. Rev. Med. 62, 141–155 (2011).
15. Friis-Møller, N. et al. Cardiovascular disease risk factors in HIV patients—Association with antiretroviral therapy. Results from the DAD study. AIDS 17, 1179–1193 (2003).
16. Zidar, D. A. et al. Oxidized LDL levels are increased in HIV infection and may drive monocyte activation. in J. Acquir. Immune Defic. Syndr. 69, 154–160 (Lippincott Williams and Wilkins, 2015).
17. KITA, T. et al. Role of oxidized LDL in atherosclerosis. Ann. N. Y. Acad. Sci. 947, 199–206 (2006).
18. Keams, A., Gordon, J., Burdo, T. H. & Qin, X. HIV-1-associated atherosclerosis: Unraveling the missing link. J. Am. Coll. Cardiol. 69, 3084–3098 (2017).
19. Guo, H., Callaway, J. B. & Ting, J. P. Y. Inflammomas: Mechanism of action, role in disease, and therapeutics. Nat. Med. 21, 677–687 (2015).
20. Adorno, S. et al. IL-21 induces antiviral microRNA-29 in CD4 T cells to limit HIV-1 infection. Nat. Commun. 6 (2015).
21. Nazari-Jahantigh, M. et al. MicroRNA-135 promotes atherosclerosis by repressing Bcl6 in macrophages. J. Clin. Invest. 122, 4190–4202 (2012).
22. Anan, M. et al. Integrative miRNA and whole-genome analyses of epicardial adipose tissue in patients with coronary atherosclerosis. Circ Cardiovasc. Res. 109, 228–239 (2016).
23. Fang, Y., Shi, C., Manduchi, E., Civilek, M. & Davies, P. F. MicroRNA-10a regulation of proinflammatory phenotype in atheromotor endothelium in vivo and in vitro. Proc. Natl. Acad. Sci. USA. 107, 13450–13455 (2010).
24. Nicolii, S. et al. MicroRNA-mediated integration of haemodynamics and Vegf signalling during angiogenesis. Nature 464, 1196–1200 (2010).
25. Madrigal-Matute, J., Rollan, N., Aranda, J. F. & Fernández-Hernando, C. MicroRNAs and atherosclerosis. Curr. Atheroscler. Rep. 15, 322 (2013).
26. Feinberg, M. W. et al. MicroRNA regulation of atherosclerosis. Circ. Res. 118, 703–720 (2016).
27. Shao, D. et al. Potential application of microRNA profiling to the diagnosis and prognosis of HIV-1 infection. Front. Microbiol. 9 (2018).
28. Swaminathan, S., Murray, D. D. & Kelleher, A. D. The role of microRNAs in HIV-1 pathogenesis and therapy. AIDS 26, 1325–1334 (2012).
29. Su, B. et al. Potential application of microRNA profiling to the diagnosis and prognosis of HIV-1 infection. Front. Microbiol. 9 (2018).
42. Balasubramaniam, M., Pandhare, J. & Dash, C. Are microRNAs important players in HIV-1 infection? An update. Viruses 10 (2018).
43. Faccini, J. et al. Circulating MIR-155, MIR-145 and let-7c as diagnostic biomarkers of the coronary artery disease. Sci. Rep. 7 (2017).
44. Ballegaard, V. et al. MicroRNA-210, MicroRNA-331, and MicroRNA-7 are differentially regulated in treated HIV-1-infected individuals and are associated with markers of systemic inflammation. in J. Acquir. Immune Defic. Syndr. 74, e104–e113 (Lippincott Williams and Wilkins, 2017).
45. Hubert, A. et al. Elevated abundance, size, and MicroRNA content of plasma extracellular vesicles in viremic HIV-1+ patients: Correlations with known markers of disease progression. J. Acquir. Immune Defic. Syndr. 70, 219–227 (2015).
46. Yuan, N. et al. MicroRNA biomarkers associated with type 1 myocardial infarction in HIV positive individuals. AIDS https://doi.org/10.1097/QAD.0000000000002368 (2019).
47. Zhang, J. et al. MiR-132 inhibits expression of SIRT1 and induces pro-inflammatory processes of vascular endothelial inflammation through blockade of the SREBP-1c metabolic pathway. Cardiovasc. Drugs Ther. 28, 303–311 (2014).
48. Rosenfeld, M. E. Inflammation and atherosclerosis: Direct versus indirect mechanisms. Curr. Opin. Pharmacol. 13 (2013).
49. Deeks, S. G., Tracy, R. & Douek, D. C. Systemic effects of inflammation on health during chronic HIV infection. Immunity 39 (2013).
50. Davis, M. M., Tato, C. M. & Furman, D. Systems immunology: Just getting started.
51. Parks, B. W. & Lusis, A. J. Macrophage accumulation in atherosclerosis.
52. Juzenas, S. et al. Activation of GPR15 and its involvement in the biological effects of smoking. Int. J. Mol. Sci. 20 (2019).
53. Gerrity, R. G. & Naito, H. K. Ultrastructural identification of monocyte-derived foam cells in fatty streak lesions. Circulation 107, 237–244 (2003).
54. Hubert, A. et al. Elevated abundance, size, and MicroRNA content of plasma extracellular vesicles in viremic HIV-1+ patients: Correlations with known markers of disease progression. J. Acquir. Immune Defic. Syndr. 70, 219–227 (2015).
55. Parks, B. W. & Lusis, A. J. Macrophage accumulation in atherosclerosis.
56. Juzenas, S. et al. Activation of GPR15 and its involvement in the biological effects of smoking. Int. J. Mol. Sci. 20 (2019).
57. Uppal, K., Ma, C., Go, Y.-M. & Jones, D. P. xMW AS: A data-driven integration and differential network analysis tool. Bioinformatics 34, 701–702 (2018).
58. Shannon, P. et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13 (2003).
59. Yasunari, M. et al. Integrin a6b1 (CD11a/CD18) is expressed by human circulating and tissue myeloid leukocytes and mediates inflammatory signaling. PLoS ONE 9 (2014).
60. Pajak, M. & Simpson, T. I. Identification of miR-34a-target interactions by a combined network based and experimental approach. Oncotarget 8, 18088–18099 (2017).
61. Parks, B. W. & Lusis, A. J. Macrophage accumulation in atherosclerosis.
62. Juzenas, S. et al. Activation of GPR15 and its involvement in the biological effects of smoking. Int. J. Mol. Sci. 20 (2019).
63. Uppal, K., Ma, C., Go, Y.-M. & Jones, D. P. xMW AS: A data-driven integration and differential network analysis tool. Bioinformatics 34, 701–702 (2018).
64. Shannon, P. et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13 (2003).
65. Yasunari, M. et al. Integrin a6b1 (CD11a/CD18) is expressed by human circulating and tissue myeloid leukocytes and mediates inflammatory signaling. PLoS ONE 9 (2014).
66. Idzikowska, E. et al. The role of different monocyte subsets in the pathogenesis of atherosclerosis and acute coronary syndromes. Scand. J. Immunol. 82 (2015).
67. Mudd, J. C. et al. Inflammatory function of CX3CR1 + CD8 + T cells in treated HIV infection is modulated by platelet interactions. J. Infect. Dis. 214, 1808–1816 (2016).
68. Kuwahara, M. et al. Bach2-Batf interactions control Th2-type immune response by regulating the IL-4 amplification loop. Immunity 39 (2013).
69. Hubert, A. et al. Elevated abundance, size, and MicroRNA content of plasma extracellular vesicles in viremic HIV-1+ patients: Correlations with known markers of disease progression. J. Acquir. Immune Defic. Syndr. 70, 219–227 (2015).
70. Parks, B. W. & Lusis, A. J. Macrophage accumulation in atherosclerosis.
71. Uppal, K., Ma, C., Go, Y.-M. & Jones, D. P. xMW AS: A data-driven integration and differential network analysis tool. Bioinformatics 34, 701–702 (2018).
72. Shannon, P. et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13 (2003).
73. Yasunari, M. et al. Integrin a6b1 (CD11a/CD18) is expressed by human circulating and tissue myeloid leukocytes and mediates inflammatory signaling. PLoS ONE 9 (2014).
74. Engelbertsen, D. et al. IL-1R and MyD88 signalling in CD4+ T cells promote Th17 immunity and atherosclerosis. Cardiovasc. Res. 114, 180–187 (2018).
75. Niki, T. et al. Elevated concentration of interferon-inducible protein of 10 kD (IP-10) is associated with coronary atherosclerosis. Int. Heart J. 56 (2015).
76. Gosselin, A. et al. Peripheral blood CCR4 + CCR6 + and CCR3 + CCR6 + CCR4 + CD4 + T cells are highly permissive to HIV-1 infection. J. Immunol. 184 (2010).
77. Ploquin, M. J. et al. Elevated basal pre-infection CXCL10 in plasma and in the small intestine after infection are associated with more rapid HIV/SIV disease onset. PLoS Pathog. 12 (2016).
78. Golden, D. et al. Lymphocyte activation gene 3 and coronary artery disease. JCI Insight 1 (2016).
79. Wongurawat, T. et al. Distinctive molecular signature and activated signaling pathways in aortic smooth muscle cells of patients with myocardial infarction. Atherosclerosis 271, 237–244 (2018).
80. Shrivastava, A., Prasad, A., Kuzontkoski, P. M., Yu, J. & Groopman, J. E. Silt2N inhibits transmission of HIV-1 from dendritic cells to T-cells by modulating novel cytoskeletal elements. Sci. Rep. 5, 1–14 (2015).
81. Köks, S. & Köks, G. Activation of GPR15 and its involvement in the biological effects of smoking. Exp. Biol. Med. 242, 1207–1212 (2017).
82. Pohlmann, S. et al. Co-receptor usage of BOB/GPR15 in addition to CCR5 has no significant effect on replication of simian immunodeficiency virus in vivo. J. Infect. Dis. 180, 1494–1502 (1999).
83. de Ronde, M. W. J. et al. High miR-124-3p expression identifies smoking individuals susceptible to atherosclerosis. Atherosclerosis 263, 377–384 (2017).
84. Bai, R. et al. miR-941 as a promising biomarker for acute coronary syndrome. BMC Cardiovasc. Disord. 17, 227 (2017).
85. Reynoso, R. et al. MicroRNAs differentially present in the plasma of HIV elite controllers reduce HIV infection in vitro. Sci. Rep. 4 (2014).
86. Hart, M. et al. Identification of miR-34a-target interactions by a combined network based and experimental approach. Oncotarget 7, 34288–34299 (2016).
miR-146a, miR-146b, and miR-155 increase expression of IL-6 and IL-8.

IP-10 is highly involved in HIV infection.

miRNA regulation of cytokine genes.

The multifaceted interface between cytokines and microRNAs: An ancient mechanism.

Supplementary Information

Author contributions

Competing interests

Additional information

Correspondence and requests for materials should be addressed to J.T.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
